Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema in Routine Clinical Practice: Results from the 24-Month AURIGA Observational Study.
Donati S, Yang CH, Xu X, Mura M, Giocanti-Aurégan A, Hoerauf H, Allmeier H, Machewitz T, Johnson KT, Santoro E; AURIGA study investigators. Donati S, et al. Among authors: allmeier h. Ophthalmol Ther. 2024 Jan;13(1):161-178. doi: 10.1007/s40123-023-00829-3. Epub 2023 Nov 4. Ophthalmol Ther. 2024. PMID: 37924483 Free PMC article.
Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis.
Chaudhary V, Holz FG, Wolf S, Midena E, Souied EH, Allmeier H, Lambrou G, Machewitz T, Mitchell P; ARIES study investigators. Chaudhary V, et al. Among authors: allmeier h. Ophthalmol Ther. 2022 Jun;11(3):1119-1130. doi: 10.1007/s40123-022-00491-1. Epub 2022 Mar 18. Ophthalmol Ther. 2022. PMID: 35303285 Free PMC article.
Real-World Management of Macular Edema Secondary to Retinal Vein Occlusion with Intravitreal Aflibercept: 24-month Results from the AURIGA Observational Study.
Giocanti-Aurégan A, Donati S, Hoerauf H, Allmeier H, Rittenhouse KD, Machewitz T, Yang CH; AURIGA Study Investigators. Giocanti-Aurégan A, et al. Among authors: allmeier h. Ophthalmol Ther. 2024 Jan;13(1):179-203. doi: 10.1007/s40123-023-00830-w. Epub 2023 Nov 4. Ophthalmol Ther. 2024. PMID: 37924481 Free PMC article.
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration.
Korobelnik JF, Chaudhary V, Mitchell P, Kang SW, Tadayoni R, Allmeier H, Lee J, Zhang X, Machewitz T, Bailey C. Korobelnik JF, et al. Among authors: allmeier h. Ophthalmol Ther. 2024 Mar;13(3):725-738. doi: 10.1007/s40123-023-00867-x. Epub 2024 Jan 10. Ophthalmol Ther. 2024. PMID: 38198053 Free PMC article.
[Aflibercept in a real-world setting: the AURIGA study : 24-month results of the German cohort of treatment-naïve patients with macular edema following retinal vein occlusion receiving intravitreal aflibercept].
Wachtlin J, Kaymak H, Hoerauf H, Allmeier H, Machewitz T, Scholz P, Schürks M, Feltgen N. Wachtlin J, et al. Among authors: allmeier h. Ophthalmologie. 2024 Aug;121(8):650-657. doi: 10.1007/s00347-024-02051-3. Epub 2024 Jul 8. Ophthalmologie. 2024. PMID: 38976039 German.
[Aflibercept in the clinical routine: the AURIGA study : The 24-month results of the German cohort of treatment-naïve patients with diabetic macular edema receiving intravitreal aflibercept].
Ulbig M, Brinkmann CK, Mirshahi A, Hoerauf H, Allmeier H, Machewitz T, Scholz P, Keramas G, Khoramnia R; Studienärzte der AURIGA-Studie. Ulbig M, et al. Among authors: allmeier h. Ophthalmologie. 2024 Nov;121(11):894-903. doi: 10.1007/s00347-024-02110-9. Epub 2024 Sep 17. Ophthalmologie. 2024. PMID: 39287660 German.
2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2 mg in patients with nAMD in clinical practice: XTEND study UK cohort.
Bailey C, Chandran M, Gale R, Narendran N, Talks J, McGoey H, Keshk Z, Morgan-Warren P, Allmeier H, Machewitz T, Patel PJ, Varma D. Bailey C, et al. Among authors: allmeier h. Eye (Lond). 2024 Dec 24. doi: 10.1038/s41433-024-03550-y. Online ahead of print. Eye (Lond). 2024. PMID: 39719502
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial.
Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, Lambrou G, Schmelter T, Wolf S; ARIES study investigators. Mitchell P, et al. Among authors: allmeier h. Retina. 2021 Sep 1;41(9):1911-1920. doi: 10.1097/IAE.0000000000003128. Retina. 2021. PMID: 33782365 Free PMC article. Clinical Trial.
16 results